AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00125957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00557999 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Application of mechanical ventilation weaning protocol
Description: Application protocol for 8 months in experimental group
Study NCT00557999 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Application of mechanical ventilation weaning protocol
Description: Application protocol for 8 months in experimental group
Study NCT00988013 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IM-TMI (3Gy)
Description: Patients will receive 3Gy per day for 1 day.
Study NCT00988013 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IM-TMI (6Gy)
Description: Patients will receive 3Gy per day for 2 days.
Study NCT00988013 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IM-TMI (9Gy)
Description: Patients will receive 3Gy per day for 3 days.
Study NCT00988013 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IM-TMI (12Gy)
Description: Patients will receive 3Gy per day for 4 days.
Study NCT00305435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim (AMG-531)
Description: Romiplostim (AMG-531)
Study NCT04005157 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MWA
Description: Patients diagnosed with early-stage NSCLC and signing the informed consent will undergo MWA with the guidance of ENB.
Study NCT04005157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENB
Description: ENB (LungCare Medical Technologies Ltd., Inc, Suzhou, China)will be used to guide bronchoscope into the accurate location of the lesion during MWA.
Study NCT02924493 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diet low in fermentable carbohydrates (low FODMAP diet)
Description: The participants follow the diet in 4 weeks. They have been provided with some foods (bread, pasta, cereal products), but will by the rest themselves. They have been provided with lists of foods to include and foods to avoid. They have also been provided with suggestions to a 4 week meal plan, based in their individual need for energy.
Study NCT02924493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet low in fermentable carbohydrates (low FODMAP diet)
Description: The participants follow the diet in 4 weeks. They have been provided with some foods (bread, pasta, cereal products), but will by the rest themselves. They have been provided with lists of foods to include and foods to avoid. They have also been provided with suggestions to a 4 week meal plan, based in their individual need for energy.
Study NCT03832335 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of aniseikonia tolerance
Description: Adding sizeglasses of different percent before right and left eye and measure the impact on stereopsis
Study NCT05173909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS closed-loop target controlled infusion
Description: BIS was monitored by connecting the BIS monitor (BISXP, Aspects Medical Systems, USA). The corresponding value was set on the BIS detector and connected to the targy-controlled infusion pump to automatically adjust the plasma drug concentration of propofol
Study NCT03178604 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic massage
Description: It involves applying the classic massage techniques: effleurage (gliding or sliding movement over the skin with a smooth continuous motion following the direction of the muscle fibers of the superficial muscles in a distal to proximal direction); petrissage (lifting, wringing, or squeezing of soft tissues in a kneading motion, or pressing or rolling of the tissues under or between the hands); tapotement (various parts of the hand striking the tissues at a fairly rapid rate). The general objective is to improve extensibility of muscle, tendon, fascia, joint capsule, and ligamentous structures.
Study NCT03178604 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham massage
Description: This group received a placebo intervention at the same time as the other group, maintaining only soft touch with the participant without exerting any mechanical pressure.
Study NCT03652935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Study NCT03652935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Series
Description: This is an active comparator condition that consists of 8 weekly classes related to health.
Study NCT04634149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Specified dose on specified days
Study NCT00884234 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control
Description: Two sequential doses of Vehicle Control at Baseline (Day 0) and Week 2
Study NCT00884234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RT001 (Botulinum Toxin Type A Topical Gel)
Description: Two sequential doses of RT001 at Baseline (Day 0) and Week 2
Study NCT02140034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extensive Peritoneal Lavage
Study NCT02652975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venous occlusion plethysmography
Description: To characterize endothelial function in vivo the effect of vasodilatating substances is measured in the forearm circuit. The substances is administered via a thin catheter placed in the Brachial artery near the elbow in local anesthesia. Once the vessels dilate, the blood flow in the forearm will increase and the flow change is a measure of the vasodilatory capacity of that substance. The change is measured with classical venous occlusion plethysmography. The method described is established at Aarhus University Hospital and has been used for several decades to illustrate the effect of vasoactive drugs on the human circulation, meaning it is a proven and well documented method.
Study NCT02652975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SphygmoCor
Description: Applanation tonometry (pulse wave velocity and central blood pressure/arterial stiffness): The central blood pressure and the augmentation index is estimated from the shape of the radial pulse wave measured with a tonometer.~Pulse wave velocity (PWV) is calculated from the average difference between the pulse pressure wave measured with a tonometer and the R in an ECG recorded simultaneously.
Study NCT03213808 — intervention group
Intervention type: OTHER
Intervention: No intervention: analysis of health data from patients with
Description: No intervention: analysis of health data from patients with respiratory allergies (asthma, rhinitis), skin allergies (dermatitis, urticarial, angioedema), anaphylaxis, gastrointestinal allergic conditions and ocular allergies (conjunctivitis) for the validation of the chapter allergies and hypersensitivity in the future version of the WHO CIM
Study NCT02650661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online health management program
Description: Web-based health management program designed according to SMASH strategy, which includes (i) Assessment, (ii) Acceptance, (iii) Preparation for change, (iv) Commitment, (v) Planning, (vi) Promoting environment, (vii) Execution, (viii) Feedback and Maintenance, and (ix) Core perspectives, for 6 months.~The program consists of four areas: self-assessment, self-planning, self-learning, and self-monitoring. The learning session includes SMASH strategies and 10 Rules for Highly Effective Health Behavior.
Study NCT02650661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: Personalized tele-coaching for 6 months by health coaches who were trained by the Smart Management and Coaching for Health (SMACH) program
Study NCT02650661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workshop
Description: Total three sessions are to be held at 3-, 5-, and 7-month after the initiation of the enrollment. Each session includes 30-minute health education, 1-hour health management strategy workshop, and 30-minute team coaching.
Study NCT02650661 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard health educational booklet
Description: Standard health educational booklets about 10 Rules for Highly Effective Health Behavior that are organized according to the Trans-theoretical Model (TTM).~Booklets are provided at 0-, 2-, and 4-month after the enrollment.
Study NCT01628822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active relaxation
Description: The length of follow-up will be 12 weeks.Patients will be seen once every seven days by a relaxation therapist for 5 weeks (6 sessions) and will be followed by the center physician investigator regarding drug therapy
Study NCT01628822 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients are been asked to relax alone in a quiet room. They are coming every 7 days for 5 weeks (6 sessions) and will be followed by the investigator regarding drug therapy
Study NCT02806206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of a placebo pill will be given to each study participant just before the ingestion of the capsule endoscopy pill.
Study NCT02679755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
Study NCT02679755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg/d tablets orally on a continuous regimen
Study NCT04158466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kalifilcon A Daily Disposable Contact Lenses
Description: Contact lens
Study NCT04158466 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biotrue ONEday Daily Disposable Contact Lenses
Description: Contact lens
Study NCT02996838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3234
Description: TQ-B3234 p.o. qd
Study NCT00965562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine 20 mg per day for 4 menstrual cycles. For the fifth menstrual cycle, all women will receive calcium. Women on Fluoxetine will continue taking it in addition to 1200mg of calcium.
Study NCT00965562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: 1200 mg of calcium to be taken for 5 menstrual cycles.
Study NCT00965562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For 5 cycles, women will receive placebo. At the end of the fourth cycle, all women will receive 1200 mg of calcium in addition to the placebo medication.
Study NCT03015428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychoeducation
Description: Providing knowledge and skills development in family caregivers of people with dementia, through a structured psychoeducational programme
Study NCT03553056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NZ Step Away app
Description: Access to 10 modules of the app (namely: drinkers profile, goal setting, rewards, cravings, strategies, support, reminders, high risk times, moods, activities)
Study NCT03553056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified NZ Step Away app
Description: Access to 2 modules of the app (namely: drinkers profile and goals setting)
Study NCT03448562 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPVI
Description: ablate around the pulmonary vein orifice
Study NCT04755608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Intensity Exercises with Blood Flow Restriction
Description: In the exercise protocol, people exercised resistance between 20% and 30% of 1 MaxRepetition with free weight. In addition, blood flow was restricted in 70% of the arterial occlusion pressure of the individual with the help of a cuff during exercise.
Study NCT04755608 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Resistant Exercise
Description: People included in the study did resistance exercise with free weight at 70-80% of 1 MT.
Study NCT04014062 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: INTP5
Description: INTP5: A proposed pegfilgrastim biosimilar to US Neulasta.
Study NCT04014062 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: INTP5
Description: INTP5: A proposed pegfilgrastim biosimilar to US Neulasta.
Study NCT04014062 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: US Neulasta
Description: US Neulasta: FDA-approved pegfilgrastim innovator product.
Study NCT04014062 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: US Neulasta
Description: US Neulasta: FDA-approved pegfilgrastim innovator product.
Study NCT02328248 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biological patch
Description: Use biological patch as opposed to plastic patch to repair hiatal hernia laparoscopically
Study NCT01635595 — intervention group
Intervention type: PROCEDURE
Intervention: Subtotal esophagectomy and gastric pull up
Description: Subtotal esophagectomy and gastric pull up and radical thoracic (2,3,4R,7,8,9)and abdominal (15,16,17,18,19,20) lymphadenectomy
Study NCT01635595 — intervention group
Intervention type: PROCEDURE
Intervention: Subtotal esophagectomy at the azygos vein, total gastrectomy
Description: Subtotal esophagectomy at the azygos vein, total gastrectomy and esophagojejunostomy and radical thoracic (2,3,4R,7,8,9) abdominal (15,16,17,18,19,20) lymphadenectomy.
Study NCT02610777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Azacitidine intravenous or subcutaneous formulation.
Study NCT02610777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine intravenous or subcutaneous formulation.
Study NCT03448562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPVI
Description: ablate around the pulmonary vein orifice
Study NCT01452204 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pulsed Electromagnetical Field and Exercise
Description: G1: MT, three times per week lasting 30' each session. G2: placebo MT, 3 X week lasting 30'each session. After 3 weeks of application of MT, will begin a program of exercises.
Study NCT03448562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STABLE-SR
Description: homogenization of the low voltage zones and elimination of the complex electrograms from the transitional zones during sinus rhythm
Study NCT01452204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetical Field and Exercise
Description: G1: MT, three times per week lasting 30' each session. G2: placebo MT, 3 X week lasting 30'each session. After 3 weeks of application of MT, will begin a program of exercises.
Study NCT02232958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Treatment
Description: Patients are placed in a special chamber in which the pressure is gradually increased up to the desired pressure with 100% Oxygen and the patient is kept at that pressure for one hour. Then the Oxygen flow is slowly reduced until the patient has been returned to one atmosphere of pressure.
Study NCT02195882 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise program of the scapular muscle stabilizers
Study NCT00913874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)
Study NCT00913874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depakote 500 mg DR Tablets (Abbott Laboratories, USA)
Study NCT03728166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic alert
Description: On-screen electronic alert that notifies the provider about the increased risk for VTE after discharge and indication for thromboprophylaxis will be issued 48 hours after admission. This first on-screen electronic alert will provide the clinician with the opportunity to consider extended-duration, post-discharge thromboprophylaxis and start any required processes for prior authorization or medication coverage. The provider then will be given on-screen options to either order thromboprophylaxis (betrixaban or low-molecular weight heparin for 35 days) from a Extended-Duration VTE Prevention order template, follow a link to evidence-based practice guidelines, or defer prescribing extended-duration, post-discharge thromboprophylaxis.
Study NCT01904266 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GA + paravertebral block
Description: 20 cc ropivacaine 0.2% will be administered in an ultrasound-guided paravertebral block
Study NCT01904266 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: GA + sham block
Description: Injection of 1 cc saline subcutaneously
Study NCT01874821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynasplint
Description: Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen
Study NCT01874821 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: The current Standard of Care for treating this condition includes corticosteroid injections and physical therapy.
Study NCT01874821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The current Standard of Care for treating this condition includes corticosteroid injections and physical therapy.
Study NCT00994123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121
Description: MM-121 (SAR256212) = intravenous solution
Study NCT00994123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: erlotinib = daily oral tablet
Study NCT00994123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: erlotinib = daily oral tablet
Study NCT03172910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciraparantag
Description: Ciraparantag (administered over 10 minutes)
Study NCT03172910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline for injection
Study NCT03172910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 20 mg given once per day (QD) in the morning
Study NCT03172910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rivaroxaban
Description: Rivaroxaban 20 mg given once per day (QD) in the morning
Study NCT03377803 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: VP-102 - Cantharidin, Topical Film Forming Solution
Description: VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Up to 4 applications of VP-102 will be administered to Molluscum lesions at 21-day intervals.
Study NCT03869541 — intervention group
Intervention type: OTHER
Intervention: Mobilization
Description: Physical rehabilitation
Study NCT00472368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Study NCT03377803 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo -Topical Film Forming Solution without VP-102
Description: Placebo a single-use drug device combination product containing only the vehicle. Up to 4 applications of Placebo will be administered to Molluscum lesions at 21-day intervals.
Study NCT02610777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Pevonedistat intravenous infusion.
Study NCT02871635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501
Study NCT04773366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone+Cytarabine+vincristine
Description: Group 1 initial treatment (W1\~W6). Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6; Cytarabine 100mg/m2 iv/IH d1-4 q2w (w1,3,5)
Study NCT02871635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 695501
Study NCT02871635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HUMIRA
Study NCT01460134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-1127
Description: Patients will initially receive a single dose of CDX-1127, followed by a 28-day observation period and a Multi-Dose Phase (one cycle of 4 weekly doses of CDX-1127). All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.~The dose of CDX-1127 given for the Dose Escalation phase will depend on the cohort each patient is assigned to, and will range between 0.1 and 10.0 mg/kg of CDX-1127.
Study NCT01460134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-1127
Description: Patients will receive 4 weekly doses of CDX-1127 followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.